Twist Bioscience (NASDAQ:TWST) collaborates with Schrödinger, Inc., to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.
Under the terms of the agreement, Schrödinger will use its physics-based computational platform to model functional antibody segments that bind to a particular GPCR receptor.
Twist Biopharma, a division of Twist Bioscience, will use its silicon-based DNA synthesis platform to generate a large number of defined antibody sequences that can then be taken into proof-of-concept and preclinical development.
The companies will collaborate on any commercial opportunities generated by the work together.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.